Kersun Biopharma

Kersun Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative drugs for oncology and autoimmune diseases, with a primary emphasis on the cGAS-STING signaling pathway. Based in Shanghai, China, the company utilizes its proprietary platform to design small molecule modulators that target the innate immune system's response. Its lead program, KS-001, is a STING agonist currently in Phase 1 clinical development for patients with advanced solid tumors. Kersun's pipeline also includes next-generation STING agonists and inhibitors aimed at treating chronic inflammation and autoimmune disorders. The company was founded in 2021 by experienced industry veterans and is supported by leading healthcare investors.